Chronic inflammation in multiple sclerosis — seeing what was always there

[1]  D. Ramasamy,et al.  Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study , 2019, American Journal of Neuroradiology.

[2]  H. Kolb,et al.  Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of 18F-JNJ-64413739, a PET Radioligand for P2X7 Receptors , 2019, The Journal of Nuclear Medicine.

[3]  B. Becher,et al.  Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation , 2019, Science Immunology.

[4]  Wojciech G. Lesniak,et al.  PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R) , 2019, Proceedings of the National Academy of Sciences.

[5]  Kathleen C. Kobashi,et al.  Only the ‘tip of the iceberg’ , 2019, Arab journal of urology.

[6]  H. Weiner,et al.  Pro‐inflammatory activation of microglia in the brain of patients with sepsis , 2018, Neuropathology and applied neurobiology.

[7]  D. Arnold,et al.  Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions , 2018, Multiple sclerosis.

[8]  F. Barkhof,et al.  In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET , 2018, Journal of Neuroinflammation.

[9]  Maiken Nedergaard,et al.  The glymphatic pathway in neurological disorders , 2018, The Lancet Neurology.

[10]  P. Bhargava,et al.  Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studies. , 2018, Multiple sclerosis and related disorders.

[11]  Siegfried Trattnig,et al.  The influence of brain iron and myelin on magnetic susceptibility and effective transverse relaxation - A biochemical and histological validation study , 2018, NeuroImage.

[12]  R. Banati,et al.  Cellular Sources and Regional Variations in the Expression of the Neuroinflammatory Marker Translocator Protein (TSPO) in the Normal Brain , 2018, International journal of molecular sciences.

[13]  R. Reynolds,et al.  MRI of cortical lesions and its use in studying their role in MS pathogenesis and disease course , 2018, Brain pathology.

[14]  Christopher C. Overall,et al.  CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature , 2018, Nature Neuroscience.

[15]  N. Sibson,et al.  Optimization of molecularly targeted MRI in the brain: empirical comparison of sequences and particles , 2018, International journal of nanomedicine.

[16]  Jeih-San Liow,et al.  Evaluation of Two Potent and Selective PET Radioligands to Image COX-1 and COX-2 in Rhesus Monkeys , 2018, The Journal of Nuclear Medicine.

[17]  M. Calabrese,et al.  The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis , 2018, Neurology.

[18]  H. Lassmann,et al.  The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells , 2018, Brain : a journal of neurology.

[19]  Pascal Sati,et al.  Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination , 2018, Brain : a journal of neurology.

[20]  B. Pakkenberg,et al.  Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex , 2018, Neuropathology and applied neurobiology.

[21]  M. Absinta,et al.  Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI , 2018, American Journal of Neuroradiology.

[22]  A. Cross,et al.  Disease-Modifying Treatment in Progressive Multiple Sclerosis , 2018, Current Treatment Options in Neurology.

[23]  M. Staufenbiel,et al.  Innate immune memory in the brain shapes neurological disease hallmarks , 2018, Nature.

[24]  B. Ertl-Wagner,et al.  TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing–remitting multiple sclerosis , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  E. Costantini,et al.  The Role of Immunosenescence in Neurodegenerative Diseases , 2018, Mediators of inflammation.

[26]  P. Tomà,et al.  Gadolinium-Based Contrast Agent-Related Toxicities , 2018, CNS Drugs.

[27]  S. Ametamey,et al.  Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor. , 2018, Journal of labelled compounds & radiopharmaceuticals.

[28]  Clare Baecher-Allan,et al.  Multiple Sclerosis: Mechanisms and Immunotherapy , 2018, Neuron.

[29]  C. V. van Eden,et al.  Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis , 2018, Acta Neuropathologica.

[30]  D. Ramasamy,et al.  Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis , 2018, American Journal of Neuroradiology.

[31]  H. Weiner,et al.  Dominant role of microglial and macrophage innate immune responses in human ischemic infarcts , 2017, Brain pathology.

[32]  Roger N Gunn,et al.  11C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than 11C-(R)-PK11195 , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  D. Nutt,et al.  Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain , 2014, The Journal of Nuclear Medicine.

[34]  P. Matthews,et al.  Achievements and obstacles of remyelinating therapies in multiple sclerosis , 2017, Nature Reviews Neurology.

[35]  L. Marti-bonmati,et al.  Retención de compuestos de gadolinio usados en resonancia magnética: revisión crítica y recomendaciones de las agencias regulatorias , 2017 .

[36]  M. Esiri,et al.  Age‐related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis , 2017, Brain pathology.

[37]  P. Matthews,et al.  Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis , 2017, Brain : a journal of neurology.

[38]  S. Ziegler,et al.  TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis , 2017, EJNMMI Research.

[39]  P. Matthews,et al.  Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis , 2017, Multiple sclerosis.

[40]  X. Montalban,et al.  Progressive MS trials: Lessons learned , 2017, Multiple sclerosis.

[41]  M. Sormani,et al.  Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials , 2017, Neurotherapeutics.

[42]  D. Ramasamy,et al.  Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study , 2017, Multiple sclerosis.

[43]  Heike E. Daldrup-Link,et al.  Ten Things You Might Not Know about Iron Oxide Nanoparticles , 2017, Radiology.

[44]  R. Liblau,et al.  Endothelial cells and lymphatics at the interface between the immune and central nervous systems: implications for multiple sclerosis , 2017, Current opinion in neurology.

[45]  Simon Hametner,et al.  Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis , 2017, Brain : a journal of neurology.

[46]  P. Matthews,et al.  Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  M. Wattjes,et al.  Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. , 2017, The British journal of radiology.

[48]  A. Bharatha,et al.  Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis , 2017, Current Treatment Options in Neurology.

[49]  Md Maqusood Alam,et al.  Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases , 2017, Nuclear Medicine and Molecular Imaging.

[50]  P. Matthews,et al.  11C-PBR28 and 18F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis , 2017, The Journal of Nuclear Medicine.

[51]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[52]  J. Correale,et al.  Progressive multiple sclerosis: from pathogenic mechanisms to treatment. , 2016, Brain : a journal of neurology.

[53]  L. Lönn,et al.  Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society , 2016, Acta neurologica Scandinavica.

[54]  L. Martí-Bonmatí,et al.  Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies. , 2017, Radiologia.

[55]  R. Bakshi,et al.  Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review , 2017, JAMA neurology.

[56]  Siegfried Trattnig,et al.  Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging , 2016, Acta Neuropathologica.

[57]  S. T. Govindarajan,et al.  Neuroinflammatory component of gray matter pathology in multiple sclerosis , 2016, Annals of neurology.

[58]  B. Caffo,et al.  Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity , 2016, American Journal of Neuroradiology.

[59]  F. Causin,et al.  Cortical relapses in multiple sclerosis , 2016, Multiple sclerosis.

[60]  D. Sharp,et al.  Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  Amit Bar-Or,et al.  Central nervous system inflammation across the age span. , 2016, Current opinion in neurology.

[62]  Gavin Giovannoni,et al.  A practical review of the neuropathology and neuroimaging of multiple sclerosis , 2016, Practical Neurology.

[63]  F. Lublin,et al.  Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS , 2016, PloS one.

[64]  J. Iliff,et al.  Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease. , 2016, Biochimica et biophysica acta.

[65]  S. Ludwin,et al.  MicroRNA Expression Patterns in Human Astrocytes in Relation to Anatomical Location and Age , 2016, Journal of neuropathology and experimental neurology.

[66]  A. Traboulsee,et al.  FLAIR2: A Combination of FLAIR and T2 for Improved MS Lesion Detection , 2016, American Journal of Neuroradiology.

[67]  K. Blennow,et al.  Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone , 2016, Multiple sclerosis.

[68]  J. Knoefel,et al.  The neuropathology and cerebrovascular mechanisms of dementia , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[69]  D. Ontaneda,et al.  Imaging as an Outcome Measure in Multiple Sclerosis , 2016, Neurotherapeutics.

[70]  Hans Lassmann,et al.  An updated histological classification system for multiple sclerosis lesions , 2016, Acta Neuropathologica.

[71]  Istvan Pirko,et al.  Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque , 2015, Annals of neurology.

[72]  C. Oreja-Guevara,et al.  Overview of magnetic resonance imaging for management of relapsing−remitting multiple sclerosis in everyday practice , 2015, European journal of neurology.

[73]  R. Reynolds,et al.  Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients , 2015, PloS one.

[74]  M. Steenwijk,et al.  MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update , 2015, Clinical Neuroradiology.

[75]  D. Reich,et al.  Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis , 2015, Neurology.

[76]  Timothy J Keyes,et al.  Structural and functional features of central nervous system lymphatics , 2015, Nature.

[77]  Britta Engelhardt,et al.  Brain barriers: Crosstalk between complex tight junctions and adherens junctions , 2015, The Journal of cell biology.

[78]  B. Trapp,et al.  Astrocyte response to IFN-γ limits IL-6-mediated microglia activation and progressive autoimmune encephalomyelitis , 2015, Journal of Neuroinflammation.

[79]  C. Louapre,et al.  Advanced imaging tools to investigate multiple sclerosis pathology. , 2015, Presse medicale.

[80]  S. Eberhardt,et al.  Iron-based superparamagnetic nanoparticle contrast agents for MRI of infection and inflammation. , 2015, AJR. American journal of roentgenology.

[81]  D. Ontaneda,et al.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives , 2015, The Lancet Neurology.

[82]  B. Trapp,et al.  Pathological mechanisms in progressive multiple sclerosis , 2015, The Lancet Neurology.

[83]  E. Shimosegawa,et al.  11C-Acetate PET Imaging in Patients with Multiple Sclerosis , 2014, PloS one.

[84]  D. Kosec,et al.  Age-associated changes in rat immune system: Lessons learned from experimental autoimmune encephalomyelitis , 2014, Experimental Gerontology.

[85]  D. Mahad,et al.  The Central Role of Mitochondria in Axonal Degeneration in Multiple Sclerosis Topical Review , 2022 .

[86]  Richard Nicholas,et al.  In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with 18F-PBR111 PET , 2014, The Journal of Nuclear Medicine.

[87]  R. Parkkola,et al.  In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand 11C-PK11195 , 2014, The Journal of Nuclear Medicine.

[88]  G. Ingram,et al.  Complement activation in multiple sclerosis plaques: an immunohistochemical analysis , 2014, Acta Neuropathologica Communications.

[89]  S. Weigand,et al.  Pathologic heterogeneity persists in early active multiple sclerosis lesions , 2014, Annals of neurology.

[90]  Roger N Gunn,et al.  Determination of [11C]PBR28 Binding Potential in vivo: A First Human TSPO Blocking Study , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[91]  E. Rostrup,et al.  Abnormal blood–brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI☆☆☆ , 2013, NeuroImage: Clinical.

[92]  H. Lassmann,et al.  Pathology of multiple sclerosis and related inflammatory demyelinating diseases. , 2014, Handbook of clinical neurology.

[93]  M. Filippi.  MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment , 2014, Journal of Neurology.

[94]  Simon Hametner,et al.  Iron and neurodegeneration in the multiple sclerosis brain , 2013, Annals of neurology.

[95]  Tracy J. Yuen,et al.  M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination , 2013, Nature Neuroscience.

[96]  Magnetic Resonance Spectroscopy to Assess NeuroInflammation and Neuropathic Pain , 2013, Journal of Neuroimmune Pharmacology.

[97]  T. Olsson,et al.  Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers , 2013, PloS one.

[98]  F Barkhof,et al.  Multicontrast Mr Imaging at 7 T in Multiple Sclerosis: Highest Lesion Detection in Cortical Gray Matter with 3d-flair 2.2 Multicontrast Mri at 7 T in Ms , 2022 .

[99]  A. Gass,et al.  Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis , 2013, Multiple sclerosis.

[100]  W. Brück,et al.  Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons , 2013, Acta Neuropathologica.

[101]  C. Rae.  A Guide to the Metabolic Pathways and Function of Metabolites Observed in Human Brain 1H Magnetic Resonance Spectra , 2013, Neurochemical Research.

[102]  Hans Lassmann,et al.  Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.

[103]  David H. Miller,et al.  Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. , 2012, Radiology.

[104]  H. Weiner,et al.  The innate immune system in demyelinating disease , 2012, Immunological reviews.

[105]  Reto Meuli,et al.  MP2RAGE Multiple Sclerosis Magnetic Resonance Imaging at 3 T , 2012, Investigative radiology.

[106]  G. Bailie.  Comparison of rates of reported adverse events associated with i.v. iron products in the United States. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[107]  Ove Almkvist,et al.  Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG , 2012, The Journal of Nuclear Medicine.

[108]  Roger N Gunn,et al.  An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[109]  D. Hafler,et al.  Multiple sclerosis. , 2012, The Journal of clinical investigation.

[110]  H. Engler,et al.  Imaging astrocytosis with PET in Creutzfeldt-Jakob disease: case report with histopathological findings. , 2012, International journal of clinical and experimental medicine.

[111]  B. Scheithauer,et al.  Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.

[112]  R. Reynolds,et al.  Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.

[113]  C. Stadelmann.  Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. , 2011, Current opinion in neurology.

[114]  R. Reynolds,et al.  The neuropathological basis of clinical progression in multiple sclerosis , 2011, Acta Neuropathologica.

[115]  Christian Langkammer,et al.  Iron and Neurodegeneration in Multiple Sclerosis , 2011, Multiple sclerosis international.

[116]  A. Prat,et al.  Disruption of central nervous system barriers in multiple sclerosis. , 2011, Biochimica et biophysica acta.

[117]  A Giorgio,et al.  Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis , 2010, Neurology.

[118]  R. Reynolds,et al.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.

[119]  R. Pazdur,et al.  FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease , 2010, American journal of hematology.

[120]  J. Antel,et al.  Thymic involution and proliferative T-cell responses in multiple sclerosis , 2010, Journal of Neuroimmunology.

[121]  P. Sørensen,et al.  Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS , 2009, Neurology.

[122]  J. Skurnick,et al.  Serum levels of CXCL13 are elevated in active multiple sclerosis , 2009, Multiple sclerosis.

[123]  X. Montalban,et al.  Predicting responders to therapies for multiple sclerosis , 2009, Nature Reviews Neurology.

[124]  Sunhee C. Lee,et al.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain , 2009, Neuropathology and applied neurobiology.

[125]  S. Amor,et al.  Preactive lesions in multiple sclerosis , 2009, Current opinion in neurology.

[126]  M. Filippi,et al.  Cortical lesions in primary progressive multiple sclerosis , 2009, Neurology.

[127]  F. Barkhof,et al.  Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)‐enhanced MRI to demonstrate diffuse inflammation in the normal‐appearing white matter (NAWM) of multiple sclerosis (MS) patients: An exploratory study , 2009, Journal of magnetic resonance imaging : JMRI.

[128]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[129]  Elizabeth Fisher,et al.  The use of MR imaging as an outcome measure in multiple sclerosis clinical trials. , 2008, Neuroimaging clinics of North America.

[130]  Marco Rovaris,et al.  Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study , 2008, NeuroImage.

[131]  Alberto Romagnolo,et al.  Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: A neuropathological study , 2008, Journal of Neuroimmunology.

[132]  F. Barkhof,et al.  Does high-field MR imaging improve cortical lesion detection in multiple sclerosis? , 2008, Journal of Neurology.

[133]  F. Rossi,et al.  Local self-renewal can sustain CNS microglia maintenance and function throughout adult life , 2007, Nature Neuroscience.

[134]  Chiara Romualdi,et al.  Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. , 2007, Archives of neurology.

[135]  J. Kirby,et al.  Role of the mucosal integrin αE(CD103)β7 in tissue‐restricted cytotoxicity , 2007 .

[136]  D. Altmann,et al.  Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes , 2007, Multiple sclerosis.

[137]  R. Ransohoff,et al.  Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Tale , 2007, Brain pathology.

[138]  S. McQuaid,et al.  Persistent endothelial abnormalities and blood–brain barrier leak in primary and secondary progressive multiple sclerosis , 2007, Neuropathology and applied neurobiology.

[139]  Colm Cunningham,et al.  Systemic infections and inflammation affect chronic neurodegeneration , 2007, Nature Reviews Immunology.

[140]  J. Kirby,et al.  Role of the mucosal integrin alpha(E)(CD103)beta(7) in tissue-restricted cytotoxicity. , 2007, Clinical and experimental immunology.

[141]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.

[142]  P. Matthews,et al.  Neocortical neuronal, synaptic, and glial loss in multiple sclerosis , 2006, Neurology.

[143]  W. Streit,et al.  Microglia in the Aging Brain , 2006, Journal of neuropathology and experimental neurology.

[144]  W. Brück.  Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis , 2005, Journal of Neurology.

[145]  Frederik Barkhof,et al.  Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. , 2005, Radiology.

[146]  Hans Lassmann,et al.  Cortical lesions and brain atrophy in MS , 2005, Journal of the Neurological Sciences.

[147]  Frederik Barkhof,et al.  Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. , 2005, AJNR. American journal of neuroradiology.

[148]  C H Polman,et al.  MR spectroscopic evidence for glial increase but not for neuro‐axonal damage in MS normal‐appearing white matter , 2005, Magnetic resonance in medicine.

[149]  Bruno Brochet,et al.  Macrophage Imaging in Central Nervous System and in Carotid Atherosclerotic Plaque Using Ultrasmall Superparamagnetic Iron Oxide in Magnetic Resonance Imaging , 2004, Investigative radiology.

[150]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[151]  B. Serafini,et al.  Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis , 2004, Journal of Neuroimmunology.

[152]  S. McQuaid,et al.  Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood–brain barrier leakage and active demyelination , 2003, The Journal of pathology.

[153]  P M Matthews,et al.  A new view of the cortex, new insights into multiple sclerosis. , 2003, Brain : a journal of neurology.

[154]  P. Matthews,et al.  Thalamic neurodegeneration in multiple sclerosis , 2002, Annals of neurology.

[155]  E. Cho,et al.  Immunopathology of secondary‐progressive multiple sclerosis , 2001, Annals of neurology.

[156]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[157]  F. Barkhof,et al.  Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets , 2001, Journal of neurology, neurosurgery, and psychiatry.

[158]  R B Banati,et al.  The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.

[159]  P. Matthews,et al.  Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. , 2000, Brain : a journal of neurology.

[160]  J. Frahm,et al.  Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. , 1999, AJNR. American journal of neuroradiology.

[161]  G. McDonnell,et al.  Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease , 1999, Journal of Neurology.

[162]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[163]  S. Reingold,et al.  The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.

[164]  Alan C. Evans,et al.  PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis , 1997, Journal of neuroscience research.

[165]  F. Barkhof,et al.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.

[166]  C. Nemeroff,et al.  Neurochemical correlates of sympathetic activation during severe alcohol withdrawal. , 1994, Alcoholism, clinical and experimental research.

[167]  J. Prineas,et al.  Blood‐Brain Barrier Abnormalities in Longstanding Multiple Sclerosis Lesions. An Immunohistochemical Study , 1994, Journal of neuropathology and experimental neurology.

[168]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[169]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.

[170]  A. S. Hall,et al.  NUCLEAR MAGNETIC RESONANCE IMAGING OF THE BRAIN IN MULTIPLE SCLEROSIS , 1981, The Lancet.

[171]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.